Sector News

Roche acquires Irish biotech firm Inflazome

September 22, 2020
Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m).

In addition to the upfront payment, Inflazome is also eligible to receive additional contingent payments, based on the achievement of predetermined milestones.

The start-up biotech was founded back in 2016 by medical researchers Professor Matt Cooper and Professor Luke O’Neill, with a focus on the development of inflammasome inhibitors.

“We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications,” said Matt Cooper, chief executive officer of Inflazome.

With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”

Following the acquisition, Roche gains full rights to Inflazome’s entire portfolio of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche has plans to further develop Inflazome’s products across a wide range of indications with high unmet medical need.

Activated NLRP3 is involved in the production of pro-inflammatory cytokines IL-1β and IL-18, which are believed to be a driving force behind several chronic inflammatory conditions.

The biotech is currently working on the development of drugs targeting inflammasomes associated with Parkinson’s disease, Alzheimer’s disease, asthma, inflammatory bowel disease, arthritis and other chronic inflammatory disease.

By: Lucy Parsons

Source: Pharma Times

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend